University Medical Centre Regensburg, Department of Gynecology and Obstetrics, 93053 Regensburg, Germany.
University Medical Centre Regensburg, Department of Gynecology and Obstetrics, 93053 Regensburg, Germany.
Clin Breast Cancer. 2022 Feb;22(2):e142-e146. doi: 10.1016/j.clbc.2021.05.010. Epub 2021 May 26.
The Invenia Automated Breast Ultrasound Screening (ABUS) is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women with high-density breast tissue. ABUS provides time-efficient evaluation of the 3-dimensional recordings within 3 to 6 minutes. The role and advantages of ABUS in everyday clinical practice, especially in routine examination during neoadjuvant chemotherapy (NACT), is not clear. The aim of this monocentric, noninterventional retrospective study is to evaluate the use of ABUS in patients who are under NACT treatment for response control.
Regular sonographic response check with handheld ultrasound (HHUS) examination and with ABUS were conducted in 83 women who underwent NACT. The response controls were conducted every 3 to 6 weeks during NACT. The handheld sonography was performed with GE Voluson S8. Handheld sonographic measurements and ABUS measurements were compared with the final pathologic tumor size.
There was no statistical difference between the measurements with HHUS examination or ABUS compared with final pathologic tumor size (P = .47). The average difference from ABUS measured tumor size to final pathologic tumor size was 9.8 mm. The average difference from handheld measured tumor size to final pathologic tumor size was 9/3 mm. Both the specificity of ABUS and HHUS examination in predicting pathologic complete remission was 100%.
ABUS seems to be a suitable method to conduct response control in neoadjuvant breast cancer treatment. ABUS may facilitate preoperative planning and offers remarkable time saving for physicians compared with HHUS examination and thus should be considered for clinical practice.
Invenia 自动乳腺超声筛查（ABUS）被指示作为一种附加手段，与乳腺 X 线摄影术联合用于高乳腺密度的无症状女性乳腺癌筛查。ABUS 可在 3 至 6 分钟内对 3 维记录进行高效评估。ABUS 在日常临床实践中的作用和优势，特别是在新辅助化疗（NACT）常规检查中尚不清楚。本单中心、非干预性回顾性研究旨在评估 ABUS 在接受 NACT 治疗的患者中用于反应控制的应用。
对 83 名接受 NACT 的患者进行常规超声反应检查（HHUS 检查）和 ABUS 检查。在 NACT 期间，每 3 至 6 周进行一次反应控制。HHUS 检查使用 GE Voluson S8 进行。HHUS 检查的测量值和 ABUS 测量值与最终病理肿瘤大小进行比较。
HHUS 检查或 ABUS 测量值与最终病理肿瘤大小之间无统计学差异（P = 0.47）。ABUS 测量的肿瘤大小与最终病理肿瘤大小的平均差值为 9.8 毫米。HHUS 测量的肿瘤大小与最终病理肿瘤大小的平均差值为 9/3 毫米。ABUS 和 HHUS 检查预测病理完全缓解的特异性均为 100%。
ABUS 似乎是一种适用于新辅助乳腺癌治疗反应控制的方法。与 HHUS 检查相比，ABUS 可促进术前计划，并为医生节省大量时间，因此应考虑将其用于临床实践。
